ISPC stock rose more than 14% on January 4, 2022, after a Craig-Hallum analyst said the company could become the Amazon of biospecimens.
Craig-Hallum bullish on iSpecimen, initiates with a Buy
Craig-Hallum analyst Matthew Hewitt initiated coverage of iSpecimen with a Buy rating and $20 price target. “Much the way Amazon has become the go-to platform for buyers and sellers of consumer goods,” the analyst believes iSpecimen can become the go-to platform for human biospecimens. While the company was founded in 2009, it has only recently reached a critical mass of buyers and sellers, with revenueThe income statement provides a summary of a company's revenue and expenses over a specified period of time, typically a year or a quarter. It shows the company's total revenue, th... for 2021 on track to be nearly triple the 2019 level, Hewitt notes.
iSpecimen to Participate in the H.C. Wainwright BioConnect Conference on January 10-13, 2022
iSpecimen Inc. (Nasdaq: ISPC) , an online marketplace for human biospecimens, today announced that Christopher Ianelli, MD, PhD, CEO and President of iSpecimen, will participate in the H.C. Wainwright BioConnect Conference to be held virtually on January 10-13, 2022. Dr. Ianelli’s corporate presentation will be available on-demand starting Monday, January 10th at 7:00 a.m. ET.
iSpecimen offers an online marketplace for human biospecimens, connecting life scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. For more information about iSpecimen, please visit https://www.ispecimen.com
iSpecimen Expands Global Biospecimen Supplier Network, Broadening Footprint Around the World
On December 16, 2021, iSpecimen Inc. (NASDAQ: ISPC), an online marketplace for human biospecimens, announced that it has expanded its global supplier network, with 25% of its newest specimen suppliers in 2021 coming from outside the United States. The expansion enhances the value of iSpecimen’s federated network of human biospecimen suppliers for research, now with more than 200 suppliers participating in the iSpecimen Marketplace. Throughout 2021, iSpecimen has added nearly two dozen biospecimen suppliers to its network, across the United States and Europe, augmenting its existing network that also includes suppliers in Asia-Pacific.
“Our expanded global coverage creates a strong foundation for international growth,” said iSpecimen Founder and CEO, Christopher Ianelli, MD, Ph.D. “We’re seeing more demand for biospecimens in Europe and Asia-Pacific, so it’s important to have the supply there as well. Ultimately, we’re providing research organizations everywhere in the world with a more diverse selection of specimens from more varied populations of patients, equipping researchers with the collections they need to expedite their work.”
iSpecimen’s expanded global coverage better serves life science research organizations by:
- Enabling researchers around the world to procure biospecimens from close to their labs, which is especially critical during global supply chain disruptions.
- Expanding biospecimen access in regions including Germany, Russia, South America, Ukraine, Bulgaria, Spain, and India to further support medical research in conditions such as autoimmune diseases, various cancers, digestive disorders, endocrine system disorders, cardiovascular disorders, pregnancy (normal, high risk, fetal abnormalities), pulmonary/respiratory tract disorders, and skin and connective tissue disorders.
- Providing researchers with a wider range of biofluids, tissue, and stem and immune cells than are available in their local geographies, including specimens with genetic variants (such as COVID-19 variants) that are more prevalent in those regions.
- Making available biospecimens that reflect diseases that are limited to certain regions of the world, or that are treated differently in those regions.
- Directly addressing the multinational procurement needs of global research organizations.
- Streamlining Biospecimen Procurement
Estimates from the Office of Biorepositories and Biospecimen Research reported in 2011 and iSpecimen’s survey of researchers performed in 2019 indicate that 4 in 5 researchers have limited the scope of their work due to the shortage of quality biospecimens. To address this challenge and accelerate scientific discovery, the iSpecimen Marketplace connects life science researchers who need biospecimens with patients and healthcare organizations that can provide them. The iSpecimen Marketplace automates search, selection, contracting, compliance/ethics (institutional review board) audits, quoting, order management, invoicing, and more.
📺 iSpecimen (ISPC) CEO On Biospecimens
[embedyt] https://www.youtube.com/watch?v=kZMatvZox70[/embedyt]📈 iSpecimen Stock Technical Analysis
The long-term trend is positive and the short-term trend is negative. It is probably better to wait until this picture becomes clearer. ISPC is part of the Health Care Technology industry. There are 51 other stocks in this industry, of which all are performing better than ISPC. ISPC is currently trading in the lower part of its 52-week range, which is not a good signal considering that the S&P500 Index is trading near new highs.
There is a support zone ranging from 7.80 to 7.80. This zone is formed by a combination of multiple trend lines in multiple time frames.
There is resistance at 11.22 from a trend line in the daily time frame. There is also resistance at 13.66 from a trend line in the daily time frame.
ISPC has an average technical rating and the quality of the presented setup is also not ideal at the moment. Price movement has been a little bit too volatile to find a nice entry and exit point. It is probably a good idea to wait for a consolidation first. Click here to sign up for email alerts on when ISPC stock consolidates and is a better entry.
